Drug Development

Listings
  • Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb5) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb2)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb2)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (hMN-14)-SN-38 ADC

    Anti-CEACAM5 (hMN-14)-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated (clone hMN-14) via a linker to SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Wit...

  • Anti-CEACAM1 (clone T84.66) scFv-dextran T-40-MMC ADC

    Anti-CEACAM1 (clone T84.66) scFv-dextran T-40-MMC ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM1 monoclonal antibody(clone T84.66) conjugated via a extran linker T-40 to a MMC.

  • Anti-CDH3-sulfo-SMCC-DM1SMe ADC

    Anti-CDH3-sulfo-SMCC-DM1SMe ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CDH3 monoclonal antibody conjugated via a sulfo-SMCC linker to DM1SMe. The DM1SMe is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within t...

  • Anti-CDH1-PBD dimers ADC

    Anti-CDH1-PBD dimers ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CDH1 monoclonal antibody conjugated via a linker to a PBD dimers. The PBD dimers is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within th...

  • Anti-CD79B-Mc-MMAF ADC

    Anti-CD79B-Mc-MMAF ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MM...

  • Anti-CD79B-MCC-DM1 ADC

    Anti-CD79B-MCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1...

  • Anti-CD79B (Polatuzumab)-Mc-VC-PABC-MMAE ADC

    Anti-CD79B (Polatuzumab)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 22, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within th...

  • Anti-CD79B (Polatuzumab)-VC-MMAE ADC

    Anti-CD79B (Polatuzumab)-VC-MMAE ADC

    Drug Development Shirley (New York) November 22, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody conjugated via a VC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, ...

  • Anti-CD79b (clone 10D10)-MCC-DM1 ADC

    Anti-CD79b (clone 10D10)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 22, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody (clone 10D10) conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...